Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.57 |
| ▸ | CDK4 | P11802 | 1/20 | 0.57 |
| ▸ | CCND1 | P24385 | 1/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7508119 | 0.95 | CCNE2 (0.56) | CCNE2CDK4CCND1CCNE1CDK2 | |
| Enmd-981693 SCHEMBL29350364 | 0.94 | CCNE2 (0.69) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7506705 | 0.94 | CDK2 (0.51) | CCNE2CDK4CCND1CCNE1CDK2 | |
| Enmd-981693 SCHEMBL608128 | 0.94 | CCNE2 (0.69) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7497956 | 0.94 | GSK3B (0.57) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7496693 | 0.93 | GSK3B (0.57) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7499634 | 0.93 | GSK3B (0.55) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7502568 | 0.93 | GSK3B (0.58) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7057352 | 0.93 | PRKCA (0.53) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7050925 | 0.92 | CCNE2 (0.49) | CCNE2CDK4CCND1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4078300-B2 | — | — | 2008-04-23 | — | — | JP | claimed |
| US-7265186-B2 | Multi-arm block copolymers as drug delivery vehicles | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-09-04 | — | — | US | claimed |
| EP-1373366-B1 | MULTI-ARM BLOCK COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS | NEKTAR THERAPEUTICS AL CORP (US) | 2005-12-21 | — | — | EP | claimed |
| US-20050147681-A1 | Multi-arm block copolymers as drug delivery vehicles | NEKTAR THERAPEUTICS | 2005-07-07 | — | — | US | claimed |
| JP-2004531627-A | — | — | 2004-10-14 | — | — | JP | claimed |
| US-6730334-B2 | COMPRISES HYDROPHOBIC CORE (POLYOL) AND HYDROPHILIC OUTER REGION; SOLUBILITY; CONTROLLED RELEASE | NEKTAR THERAPEUTICS AL, CORPORATION | 2004-05-04 | — | — | US | claimed |
| EP-1373366-A2 | MULTI-ARM BLOCK COPOLYMERS AS DRUG DELIVERY VEHICLES | Shearwater Corporation (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2003000777-A2 | MULTI-ARM BLOCK COPOLYMERS AS DRUG DELIVERY VEHICLES | SHEARWATER CORPORATION (US) | 2003-01-03 | — | — | WO | claimed |
| US-20020156047-A1 | Multi-arm block copolymers as drug delivery vehicles | SHEARWATER CORPORATION | 2002-10-24 | — | — | US | claimed |
| EP-0915870-B1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | HOFFMANN LA ROCHE (CH) | 2002-09-25 | — | — | EP | claimed |
| US-6228877-B1 | ANTICARCINOGENIC, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | HOFFMANN-LA ROCHE INC. | 2001-05-08 | — | — | US | claimed |
| EP-2214716-B1 | HYDROXYAPATITE-TARGETING MULTIARM POLYMERS AND CONJUGATES MADE THEREFROM | NEKTAR THERAPEUTICS (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20190021999-A1 | EXTREMELY SMALL NANOPARTICLES OF DEGRADABLE POLYMERS | PHOSPHOREX, INC. | 2019-01-24 | — | — | US | disclosed |
| EP-3337455-A1 | EXTREMELY SMALL NANOPARTICLES OF DEGRADABLE POLYMERS | Phosphorex Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2319542-B1 | Segmented degradable polymers and conjugates made therefrom | NEKTAR THERAPEUTICS (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20020156047-A1 | Multi-arm block copolymers as drug delivery vehicles | SHEARWATER CORPORATION | 2002-10-24 | — | — | US | disclosed |
| EP-0915870-B1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | HOFFMANN LA ROCHE (CH) | 2002-09-25 | — | — | EP | disclosed |
| US-6228877-B1 | ANTICARCINOGENIC, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | HOFFMANN-LA ROCHE INC. | 2001-05-08 | — | — | US | disclosed |
| EP-0915870-A1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004551-A1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156047-A1 | Multi-arm block copolymers as drug delivery vehicles | BCR, ABCB1, CHMP4B | CCNE2 1962/4885CDK4 470/4885CCND1 3003/4885 |
| US-20050147681-A1 | Multi-arm block copolymers as drug delivery vehicles | BCR, CHMP4B, INCENP | CCNE2 1836/4885CDK4 475/4885CCND1 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.